Case Report
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
Table 1
Patient’s history.
| | Line | Regimen | Cycle (n°) | Responses |
| | 1 | Thalidomide-dexamethasone + RT | 7 | Progressive disease | | 2 | Bortezomib-dexamethasone | 5 | Partial response | | 3 | First auto-BMT (thiotepa-melphalan) | / | Stable disease | | 4 | Lenalidomide-dexamethasone | 4 | Progressive disease | | 5 | Melphalan-lenalidomide-dexamethasone | 3 | Progressive disease | | 6 | Doxorubicin-cyclophosphamide-dexamethasone | 2 | Progressive disease | | 7 | Bendamustine-bortezomib-dexamethasone | 6 | Partial response | | 8 | Second auto-BMT (thiotepa-melphalan) | / | Stable disease | | 9 | Bortezomib-lenalidomide-dexamethasone | 6 | Progressive disease | | 10 | Bendamustine-bortezomib-dexamethasone | 7 | Stable disease | | 11 | Pomalidomide-dexamethasone | 4 | Progressive disease |
|
|
